Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8243750 | 0.87 | GAA (0.63) | EPHX1GAABCHENAAAACHE | |
| SCHEMBL20928290 | 0.87 | EPHX1 (0.65) | EPHX1GAABCHENAAAKCNA3 | |
| SCHEMBL22134964 | 0.83 | EPHX1 (0.66) | EPHX1GAABCHENAAAACHE | |
| SCHEMBL23200480 | 0.83 | EPHX1 (0.70) | EPHX1GAABCHENAAAKCNA3 | |
| SCHEMBL22136179 | 0.82 | EPHX1 (0.69) | EPHX1GAABCHENAAAACHE | |
| SCHEMBL2801495 | 0.82 | EPHX1 (0.69) | EPHX1GAABCHENAAAACHE | |
| SCHEMBL16374741 | 0.82 | EPHX1 (0.64) | EPHX1GAABCHENAAA | |
| SCHEMBL14424470 | 0.82 | EPHX1 (0.73) | EPHX1GAABCHENAAAKCNA3 | |
| SCHEMBL12991745 | 0.81 | EPHX1 (0.67) | EPHX1GAABCHENAAA | |
| SCHEMBL14703637 | 0.81 | EPHX1 (0.62) | EPHX1GAANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034220-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465653-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4048315-B1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS INC (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240091370-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-20240033370-A1 | ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-02-01 | — | — | US | disclosed |
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4259208-A1 | IMMUNOCONJUGATES COMPRISING AN ANTI-CEA ANTIBODY LINKED BY CONJUGATION TO ONE OR MORE 8-HET-2- AMINOBENZAZEPINE DERIVATIVES USEFUL IN TREATING CANCER | Bolt Biotherapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-4259212-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-4259209-A1 | ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2022125908-A1 | ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125884-A1 | IMMUNOCONJUGATES COMPRISING AN ANTI-CEA ANTIBODY LINKED BY CONJUGATION TO ONE OR|MORE 8-HET-2- AMINOBENZAZEPINE DERIVATIVES USEFUL IN TREATING CANCER | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022036101-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036101-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2021081402-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081407-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081407-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081402-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | KCNJ5, IL5, CYP3A5 | EPHX1 861/4885GAA 4096/4885PAOX 1651/4885 |
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | EPHX1 144/4885GAA 3905/4885PAOX 3864/4885 |
| US-12465653-B2 | Thienoazepine immunoconjugates, and uses thereof | ICOS, CYP3A5, TPH1 | EPHX1 144/4885GAA 3905/4885PAOX 3864/4885 |
| US-20240091370-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | ERBB2, LTB4R2, PTGER2 | EPHX1 203/4885GAA 2705/4885PAOX 3229/4885 |
| US-20260034220-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | IL2, CD47, EPCAM | EPHX1 82/4885GAA 2078/4885PAOX 4125/4885 |
| US-20240033370-A1 | ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF | PDCD1LG2, CD274, PDCD1 | EPHX1 3727/4885GAA 3456/4885PAOX 4153/4885 |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | EPHX1 144/4885GAA 3905/4885PAOX 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.